A depression drug just lost to a sugar pill three times in a row

Biotech & Longevity 3 min 80 sources

Neumora's navacaprant failed its third and final late-stage depression trial — in one study, patients on the placebo did better. The week's other results show what beating a sugar pill actually looks like.

Key takeaways

Neumora's depression drug navacaprant failed its third straight large trial; in one study patients did better on the placebo, and the company is cutting a third of its staff.
Depression is one of the hardest conditions to prove a drug works for, because the placebo response is unusually strong — feeling better is not the same as the drug working.
A GLP-1 diabetes pill beat placebo in a mid-stage trial and an mRNA flu shot faces its FDA vote this week, showing what clearing that bar looks like.

The biggest biotech story this week is a failure, and a clarifying one. On Monday, Neumora Therapeutics reported that its experimental depression drug, navacaprant, missed in its last two large trials — and with that, the drug went 0 for 3 [45]. The company is discontinuing it and cutting roughly 35% of its staff [45].

The drug that couldn’t beat a sugar pill

Navacaprant was meant to treat major depressive disorder. In the trials, it had to do one thing: help patients more than a placebo — a dummy pill with no active drug in it [45].

It didn’t. Across the Koastal-2 and Koastal-3 studies, navacaprant did not significantly outperform placebo on the standard depression rating scale by week six [45]. In the Koastal-3 study, patients on the placebo actually fared better than patients on the drug [45].

This was the third strike. Back in early 2025, the first trial, Koastal-1, also missed — sending Neumora’s stock down 80% in a day [45]. After Monday’s results the stock fell another 45%, to 98 cents; it is down about 95% from its 2025 peak [45]. To save $10 million a year, the company is laying off about a third of its people [45].

A “phase 3” trial, for the uninitiated, is the big final test before a drug can be approved — hundreds or thousands of patients, the drug measured against a placebo or the current standard [45]. Earlier phases only check that a drug is safe and shows a rough signal. Navacaprant got that far. It still couldn’t clear the last bar.

What beating the placebo actually looks like

The same week offered a contrast. At a major diabetes meeting, researchers presented SOLSTICE, a mid-stage trial of an experimental GLP-1 pill called elecoglipron for type 2 diabetes [51]. GLP-1 drugs are the class behind Ozempic and Wegovy; they curb appetite and lower blood sugar, but most are injections [51].

This one is a pill, and in the trial it significantly lowered blood sugar and reduced weight against placebo, with results published in The Lancet [51]. The caveat: it was a phase 2b study, the stage before the big final test — promising, not proven [51]. The difference from navacaprant is simply that this drug separated from the dummy pill. That separation is the whole game.

In motion: the first mRNA flu shot faces its vote

The mRNA technology behind the COVID vaccines is now knocking on the door of the flu shot. Moderna is seeking US approval for mFlusiva, which would be the first mRNA-based seasonal flu vaccine cleared in the country [43].

Ahead of an FDA advisory meeting on June 18, agency staff said the data “may support” the shot’s effectiveness in adults 65 and older, and noted it beat a standard-dose flu vaccine in people aged 50 to 64 [43]. The FDA, the US drug regulator, will hear its outside experts vote on whether the benefits outweigh the risks [43][16]. A favorable staff review is a good sign, not a decision.

Under the radar: a parasite drug for pets, fast-tracked

As a flesh-eating screwworm parasite spreads in parts of the Americas, the FDA granted emergency clearance for an over-the-counter tablet — nitenpyram — to treat infestations in pets [9]. It is fast-acting, expected to kill most larvae within hours of the first dose, and is the first generic animal drug cleared under an emergency pathway for this use [9]. It won’t prevent reinfestation, and a vet may still need to remove larvae and treat wounds [9]. A small, practical move in a larger push to contain the parasite [9].

02 · Lesson · why it matters

The hardest thing to beat in medicine is a pill with nothing in it

Feeling better is not proof that something worked — and a depression drug just lost to a sugar pill three times to remind us why.

A drug that failed at the one job that mattered

This week a company called Neumora gave up on a depression drug it had spent years and a fortune on. The drug, navacaprant, had to clear one bar: help people more than a fake pill — a placebo — would. It failed that test three separate times. In one trial, the people taking the placebo got better than the people taking the real drug.

Read that again. People swallowing a pill with no medicine in it improved more than people swallowing the actual treatment.

This is not a freak result. In depression trials, it happens constantly. Roughly half of all antidepressants that reach the final stage of testing fail to beat placebo. The puzzle isn’t why navacaprant lost. It’s why we keep being surprised when drugs do.

The placebo is not “nothing”

We use the word placebo to mean “fake” — an empty pill, a stand-in for the real thing. But in a person’s body, the placebo is doing real work.

Someone with depression who enrolls in a trial is, for the first time in a while, being seen. A doctor checks on them every week. Someone asks how they’re sleeping, how they’re eating, whether the dark thoughts came back. They have hope — they signed up because they believe this might help. All of that, on its own, lifts mood. The body responds to being cared for, to expectation, to attention. None of it is the drug.

So the placebo group doesn’t sit still. They get better too. Sometimes a lot better. The real drug isn’t competing against zero. It’s competing against the considerable power of hope and attention.

Why depression is the worst case

Every trial fights the placebo effect. Depression fights the strongest version of it.

A blood-pressure drug is easy to judge: you point a cuff at the patient and read a number that doesn’t care how anyone feels. Depression has no cuff. It is measured by asking people how they are — and how people say they are bends to mood, to who’s asking, to whether they expect to improve. The measurement itself is made of the same stuff the placebo moves.

There’s a second trap underneath. People sign up for a trial when they’re at their worst — that’s when they go looking for help. From a low point, the only likely direction is up. Some of them would have risen anyway, drug or no drug, simply because they joined at the bottom. This is called regression to the mean: extreme moments tend to be followed by ordinary ones. A drug given to people at their lowest will look like it helped, even if it did nothing, because the bottom rarely stays the bottom.

The thing you cannot trust is your own feeling

Here is where this stops being about one company’s bad week and becomes about everyone, including you.

You take something — a supplement, a new routine, a remedy a friend swore by — and a week later you feel better. The conclusion is almost irresistible: it worked. But you are a trial of one, with no placebo group, run by the one person least able to judge it: yourself. You took it because you felt bad, which means you started at a low point. You hoped it would help, which lifts mood on its own. And you, like everyone, remember the hits and forget the misses.

Your felt improvement is real. What it cannot tell you is the cause. That’s not a flaw in you — it’s the same gap that fools trained scientists running million-dollar studies, which is exactly why they built the placebo group: to subtract everything that isn’t the drug and see what’s left.

This is why the contrast in the week mattered. A diabetes pill in the same news cycle did beat its placebo, and an mRNA flu shot is up for approval on data measured against a standard. The whole apparatus of trials, controls, and dummy pills exists for one reason — because a human being, feeling better, genuinely cannot tell on their own whether the thing they took is why.

What the failed drug leaves us

It’s tempting to read navacaprant’s collapse as a story about a bad drug, or a company that overpromised. It’s really a story about how hard it is to know anything, and how much machinery we need to know it honestly.

The people in that placebo group who improved weren’t faking. The hope was real, the care was real, the lift was real. The drug just wasn’t the reason. Holding those two facts at once — I feel better and I don’t know why — is uncomfortable. It is also the most honest place to stand. The next time something makes you feel better, the improvement is yours to keep. The certainty about what caused it is the part worth holding loosely.

03 · Lab · your turn

Did It Work?

Rehearse judging whether a remedy helped you, then meet the hidden placebo person who improved just as much — and feel why your own felt improvement can't prove the cause.

04 · Hope · carry this

The drug failed, but the people in the placebo group still got better — proof that being seen, being asked how you are, and being cared for each week moves something real in us. The hardest part of healing was never only in the pill.